Inspection Record

Orimed Pharma Inc — Health Canada Inspection Findings

Health CanadaInspected 2025-01-13 3 findingsOther quality systemTraining and personnelComplaint and recall handling

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.

2Training and personnel

The training of personnel before new or revised standard operating procedures were implemented was inadequate.

3Complaint and recall handling

The written procedures for recalls were inadequate. The quality control department did not undertake all of the required activities.

About this record

Extracted automatically from the document of the Health Canada inspection on 2025-01-13. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Orimed Pharma Inc company profile — full history Health Canada documents, 2025 Go to Findings search